Symbols / GALT Stock $2.45 +7.46% Galectin Therapeutics Inc.
GALT (Stock) Chart
About
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Stock Fundamentals
Scroll to Statements| Market Cap | 161.28M | Enterprise Value | 283.49M | Income | -30.97M | Sales | — | Book/sh | -1.97 | Cash/sh | 0.27 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -1.46 |
| PEG | -36.15 | P/S | — | P/B | -1.24 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 2.21 | Current Ratio | 2.42 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.48 | EPS next Y | -1.68 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-31 | ROA | -67.81% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 65.83M | Shs Float | 47.16M | Short Float | 16.21% |
| Short Ratio | 21.73 | Short Interest | — | 52W High | 7.13 | 52W Low | 1.21 | Beta | 1.04 | Avg Volume | 323.37K |
| Volume | 289.09K | Target Price | $11.00 | Recom | None | Prev Close | $2.28 | Price | $2.45 | Change | 7.46% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-04-02 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-27 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-04-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-03-03 | reit | HC Wainwright & Co. | — → Buy | $11 |
| 2022-05-17 | main | HC Wainwright & Co. | — → Buy | $11 |
| 2021-04-16 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2020-08-13 | main | HC Wainwright & Co. | — → Buy | $12 |
| 2020-04-03 | main | B. Riley Securities | — → Buy | $4 |
| 2020-03-17 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2019-02-13 | init | B. Riley Securities | — → Buy | $11 |
| 2017-10-19 | init | Roth Capital | — → Buy | $8 |
| 2017-10-06 | init | Seaport Global | — → Buy | $5 |
| 2017-03-30 | up | HC Wainwright & Co. | Neutral → Buy | $4 |
- GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment. - Earnings Per Share - UBND thành phố Hải Phòng hu, 23 Apr 2026 03
- With no approved MASH cirrhosis drugs, Galectin takes belapectin to FDA - Stock Titan ue, 31 Mar 2026 07
- Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20 - Fast Rising Picks - Xã Vĩnh Công ue, 21 Apr 2026 03
- $GALT stock is down 12% today. Here's what we see in our data. - Quiver Quantitative hu, 16 Apr 2026 19
- Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Fri, 03 Apr 2026 07
- 10x fund sells Galectin therapeutics (GALT) shares worth $851,700 - Investing.com hu, 04 Dec 2025 08
- Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20 - Open Stock Signal Network - UBND thành phố Hải Phòng ue, 21 Apr 2026 03
- Why Did GALT Shares Plummet Over 30% Today? - Stocktwits Fri, 19 Dec 2025 08
- New funding keeps potential liver cirrhosis treatment on track to 2027 - Stock Titan Fri, 19 Dec 2025 08
- Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials - Yahoo Finance ue, 23 Sep 2025 07
- $GALT stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan ue, 17 Mar 2026 07
- $GALT stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - Stock Titan ue, 31 Mar 2026 07
- $GALT stock is down 36% today. Here's what we see in our data. | GALT Stock News - Quiver Quantitative Fri, 19 Dec 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
20.09
-52.67%
|
42.43
+11.45%
|
38.07
-0.73%
|
38.35
|
| Research And Development |
|
14.29
-60.93%
|
36.57
+13.82%
|
32.13
+1.24%
|
31.74
|
| Selling General And Administration |
|
5.79
-1.14%
|
5.86
-1.35%
|
5.94
-10.17%
|
6.62
|
| General And Administrative Expense |
|
5.79
-1.14%
|
5.86
-1.35%
|
5.94
-10.17%
|
6.62
|
| Other Gand A |
|
5.79
-1.14%
|
5.86
-1.35%
|
5.94
-10.17%
|
6.62
|
| Total Expenses |
|
20.09
-52.67%
|
42.43
+11.45%
|
38.07
-0.73%
|
38.35
|
| Operating Income |
|
-20.09
+52.67%
|
-42.43
-11.45%
|
-38.07
+0.73%
|
-38.35
|
| Total Operating Income As Reported |
|
-20.09
+52.67%
|
-42.43
-11.45%
|
-38.07
+0.73%
|
-38.35
|
| EBITDA |
|
-23.45
+43.44%
|
-41.47
-8.44%
|
-38.24
-1.41%
|
-37.71
|
| Normalized EBITDA |
|
-19.91
+52.67%
|
-42.06
-11.24%
|
-37.81
+1.20%
|
-38.27
|
| Reconciled Depreciation |
|
0.05
+43.24%
|
0.04
+12.12%
|
0.03
+3.13%
|
0.03
|
| EBIT |
|
-23.51
+43.37%
|
-41.51
-8.45%
|
-38.27
-1.41%
|
-37.74
|
| Total Unusual Items |
|
-3.55
-703.40%
|
0.59
+236.11%
|
-0.43
-177.56%
|
0.56
|
| Total Unusual Items Excluding Goodwill |
|
-3.55
-703.40%
|
0.59
+236.11%
|
-0.43
-177.56%
|
0.56
|
| Net Income |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Pretax Income |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Net Non Operating Interest Income Expense |
|
-7.20
-38.47%
|
-5.20
-103.04%
|
-2.56
-161.16%
|
-0.98
|
| Interest Expense Non Operating |
|
7.33
+32.29%
|
5.54
+98.42%
|
2.79
+170.28%
|
1.03
|
| Net Interest Income |
|
-7.20
-38.47%
|
-5.20
-103.04%
|
-2.56
-161.16%
|
-0.98
|
| Interest Expense |
|
7.33
+32.29%
|
5.54
+98.42%
|
2.79
+170.28%
|
1.03
|
| Interest Income Non Operating |
|
0.13
-62.72%
|
0.34
+46.96%
|
0.23
+342.31%
|
0.05
|
| Interest Income |
|
0.13
-62.72%
|
0.34
+46.96%
|
0.23
+342.31%
|
0.05
|
| Other Income Expense |
|
-3.55
-703.40%
|
0.59
+236.11%
|
-0.43
-177.56%
|
0.56
|
| Gain On Sale Of Security |
|
-3.55
-703.40%
|
0.59
+236.11%
|
-0.43
-177.56%
|
0.56
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Net Income From Continuing And Discontinued Operation |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Net Income Continuous Operations |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Normalized Income |
|
-27.29
+42.71%
|
-47.63
-17.23%
|
-40.63
-3.31%
|
-39.33
|
| Net Income Common Stockholders |
|
-30.97
+34.38%
|
-47.20
-5.35%
|
-44.80
-15.26%
|
-38.87
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
3.62
|
0.00
|
| Diluted EPS |
|
-0.48
+36.84%
|
-0.76
-2.70%
|
-0.74
-13.85%
|
-0.65
|
| Basic EPS |
|
-0.48
+36.84%
|
-0.76
-2.70%
|
-0.74
-13.85%
|
-0.65
|
| Basic Average Shares |
|
63.90
+2.56%
|
62.31
+3.57%
|
60.16
+1.29%
|
59.39
|
| Diluted Average Shares |
|
63.90
+2.56%
|
62.31
+3.57%
|
60.16
+1.29%
|
59.39
|
| Diluted NI Availto Com Stockholders |
|
-30.97
+34.38%
|
-47.20
-5.35%
|
-44.80
-15.26%
|
-38.87
|
| Preferred Stock Dividends |
|
0.14
-9.80%
|
0.15
+27.50%
|
0.12
+23.71%
|
0.10
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
19.53
+11.64%
|
17.50
-37.96%
|
28.20
+32.49%
|
21.29
|
| Current Assets |
|
19.44
+12.66%
|
17.25
-37.74%
|
27.71
+34.83%
|
20.55
|
| Cash Cash Equivalents And Short Term Investments |
|
17.72
+17.20%
|
15.12
-41.08%
|
25.66
+38.02%
|
18.59
|
| Cash And Cash Equivalents |
|
17.72
+17.20%
|
15.12
-41.08%
|
25.66
+38.02%
|
18.59
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.72
-19.51%
|
2.13
+4.00%
|
2.05
+4.59%
|
1.96
|
| Total Non Current Assets |
|
0.10
-60.49%
|
0.24
-50.41%
|
0.49
-33.15%
|
0.73
|
| Net PPE |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Gross PPE |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Accumulated Depreciation |
|
-0.07
+0.00%
|
-0.07
+0.00%
|
-0.07
+0.00%
|
-0.07
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Other Properties |
|
—
|
—
|
—
|
0.73
|
| Leases |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Other Non Current Assets |
|
0.10
-60.49%
|
0.24
-50.41%
|
0.49
-33.15%
|
0.73
|
| Total Liabilities Net Minority Interest |
|
145.73
+20.87%
|
120.56
+36.32%
|
88.44
+65.38%
|
53.48
|
| Current Liabilities |
|
8.03
-77.32%
|
35.41
+125.88%
|
15.68
+20.47%
|
13.01
|
| Payables And Accrued Expenses |
|
6.95
-43.85%
|
12.38
-14.62%
|
14.50
+20.85%
|
12.00
|
| Payables |
|
3.31
-42.16%
|
5.72
-11.93%
|
6.49
+64.24%
|
3.95
|
| Accounts Payable |
|
3.25
-42.63%
|
5.66
-12.05%
|
6.43
+65.32%
|
3.89
|
| Dividends Payable |
|
0.06
+0.00%
|
0.06
+0.00%
|
0.06
-1.56%
|
0.06
|
| Current Accrued Expenses |
|
3.64
-45.30%
|
6.66
-16.80%
|
8.01
-0.47%
|
8.04
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.06
-30.66%
|
1.52
+34.90%
|
1.13
+16.03%
|
0.97
|
| Current Debt And Capital Lease Obligation |
|
0.02
-99.90%
|
21.14
+45847.83%
|
0.05
+15.00%
|
0.04
|
| Current Debt |
|
—
|
21.12
|
—
|
—
|
| Other Current Borrowings |
|
—
|
21.12
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.02
+15.79%
|
0.02
-58.70%
|
0.05
+15.00%
|
0.04
|
| Other Current Liabilities |
|
—
|
0.37
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
137.70
+61.70%
|
85.16
+17.03%
|
72.77
+79.81%
|
40.47
|
| Long Term Debt And Capital Lease Obligation |
|
133.74
+57.13%
|
85.11
+18.63%
|
71.74
+80.13%
|
39.83
|
| Long Term Debt |
|
133.74
+57.13%
|
85.11
+18.63%
|
71.74
+80.13%
|
39.83
|
| Other Non Current Liabilities |
|
—
|
—
|
0.02
-69.70%
|
0.07
|
| Stockholders Equity |
|
-126.19
-22.44%
|
-103.07
-71.10%
|
-60.24
-87.12%
|
-32.19
|
| Common Stock Equity |
|
-128.41
-21.95%
|
-105.29
-68.57%
|
-62.46
-81.44%
|
-34.43
|
| Capital Stock |
|
2.28
-0.31%
|
2.29
+0.04%
|
2.28
-0.35%
|
2.29
|
| Common Stock |
|
0.07
+4.84%
|
0.06
+1.64%
|
0.06
+3.39%
|
0.06
|
| Preferred Stock |
|
2.21
-0.45%
|
2.22
+0.00%
|
2.22
-0.45%
|
2.23
|
| Share Issued |
|
65.20
+3.24%
|
63.16
+2.11%
|
61.85
+4.08%
|
59.43
|
| Ordinary Shares Number |
|
65.20
+3.24%
|
63.16
+2.11%
|
61.85
+4.08%
|
59.43
|
| Additional Paid In Capital |
|
304.07
+2.65%
|
296.22
+1.50%
|
291.85
+6.09%
|
275.08
|
| Retained Earnings |
|
-432.55
-7.71%
|
-401.57
-13.32%
|
-354.37
-14.47%
|
-309.57
|
| Total Equity Gross Minority Interest |
|
-126.19
-22.44%
|
-103.07
-71.10%
|
-60.24
-87.12%
|
-32.19
|
| Total Capitalization |
|
7.54
+141.98%
|
-17.96
-256.18%
|
11.50
+50.64%
|
7.63
|
| Working Capital |
|
11.41
+162.82%
|
-18.16
-250.88%
|
12.03
+59.60%
|
7.54
|
| Invested Capital |
|
5.33
+470.95%
|
0.93
-89.94%
|
9.28
+71.76%
|
5.40
|
| Total Debt |
|
133.76
+25.89%
|
106.25
+48.00%
|
71.79
+80.06%
|
39.87
|
| Net Debt |
|
116.02
+27.34%
|
91.11
+97.71%
|
46.08
+116.99%
|
21.24
|
| Capital Lease Obligations |
|
0.02
+15.79%
|
0.02
-58.70%
|
0.05
+15.00%
|
0.04
|
| Net Tangible Assets |
|
-126.19
-22.44%
|
-103.07
-71.10%
|
-60.24
-87.12%
|
-32.19
|
| Tangible Book Value |
|
-128.41
-21.95%
|
-105.29
-68.57%
|
-62.46
-81.44%
|
-34.43
|
| Derivative Product Liabilities |
|
3.96
+8329.79%
|
0.05
-95.32%
|
1.00
+75.22%
|
0.57
|
| Preferred Stock Equity |
|
2.21
-0.45%
|
2.22
+0.00%
|
2.22
-0.45%
|
2.23
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-23.88
+42.84%
|
-41.77
-26.70%
|
-32.97
-6.15%
|
-31.06
|
| Cash Flow From Continuing Operating Activities |
|
-23.88
+42.84%
|
-41.77
-26.70%
|
-32.97
-6.15%
|
-31.06
|
| Net Income From Continuing Operations |
|
-30.84
+34.46%
|
-47.05
-14.56%
|
-41.07
-5.91%
|
-38.78
|
| Depreciation Amortization Depletion |
|
0.05
+43.24%
|
0.04
+12.12%
|
0.03
+3.13%
|
0.03
|
| Depreciation |
|
0.05
+43.24%
|
0.04
+12.12%
|
0.03
+3.13%
|
0.03
|
| Depreciation And Amortization |
|
0.05
+43.24%
|
0.04
+12.12%
|
0.03
+3.13%
|
0.03
|
| Other Non Cash Items |
|
1.09
-0.55%
|
1.10
+57.82%
|
0.70
+70.00%
|
0.41
|
| Stock Based Compensation |
|
1.66
-32.20%
|
2.45
+8.23%
|
2.26
-21.14%
|
2.87
|
| Operating Gains Losses |
|
3.55
+703.06%
|
-0.59
-236.11%
|
0.43
+177.56%
|
-0.56
|
| Gain Loss On Investment Securities |
|
3.55
+703.06%
|
-0.59
-236.11%
|
0.43
+177.56%
|
-0.56
|
| Change In Working Capital |
|
0.61
-73.34%
|
2.28
-51.18%
|
4.68
-5.84%
|
4.97
|
| Change In Prepaid Assets |
|
0.42
+607.32%
|
-0.08
+8.89%
|
-0.09
-189.11%
|
0.10
|
| Change In Payables And Accrued Expense |
|
0.19
-91.84%
|
2.37
-50.38%
|
4.77
-2.03%
|
4.87
|
| Change In Accrued Expense |
|
6.24
+40.43%
|
4.44
+111.73%
|
2.10
+236.60%
|
0.62
|
| Change In Payable |
|
-6.04
-191.32%
|
-2.07
-177.65%
|
2.67
-37.06%
|
4.24
|
| Change In Account Payable |
|
-6.04
-191.32%
|
-2.07
-177.65%
|
2.67
-37.06%
|
4.24
|
| Investing Cash Flow |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
26.48
-15.22%
|
31.23
-22.00%
|
40.03
+300.33%
|
10.00
|
| Cash Flow From Continuing Financing Activities |
|
26.48
-15.22%
|
31.23
-22.00%
|
40.03
+300.33%
|
10.00
|
| Net Issuance Payments Of Debt |
|
21.00
-30.00%
|
30.00
+0.00%
|
30.00
+200.00%
|
10.00
|
| Issuance Of Debt |
|
21.00
-30.00%
|
30.00
+0.00%
|
30.00
+200.00%
|
10.00
|
| Long Term Debt Issuance |
|
21.00
-30.00%
|
30.00
+0.00%
|
30.00
+200.00%
|
10.00
|
| Net Long Term Debt Issuance |
|
21.00
-30.00%
|
30.00
+0.00%
|
30.00
+200.00%
|
10.00
|
| Net Common Stock Issuance |
|
3.23
|
0.00
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.24
+82.56%
|
1.23
-87.77%
|
10.03
|
0.00
|
| Changes In Cash |
|
2.60
+124.67%
|
-10.54
-249.12%
|
7.07
+133.57%
|
-21.06
|
| Beginning Cash Position |
|
15.12
-41.08%
|
25.66
+38.02%
|
18.59
-53.11%
|
39.65
|
| End Cash Position |
|
17.72
+17.20%
|
15.12
-41.08%
|
25.66
+38.02%
|
18.59
|
| Free Cash Flow |
|
-23.88
+42.84%
|
-41.77
-26.70%
|
-32.97
-6.15%
|
-31.06
|
| Change In Interest Payable |
|
6.24
+40.43%
|
4.44
+111.73%
|
2.10
+236.60%
|
0.62
|
| Common Stock Issuance |
|
3.23
|
0.00
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
3.23
|
0.00
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 10-K2026-03-31 View
- 42026-03-17 View
- 8-K2026-03-17 View
- 42026-02-09 View
- 42026-01-21 View
- 8-K2026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-13 View
- 8-K2026-01-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|